risk‐based approach to managing active pharmaceutical ingredients in manufacturing effluent

The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools...

Full description

Saved in:
Bibliographic Details
Published inEnvironmental toxicology and chemistry Vol. 35; no. 4; pp. 813 - 822
Main Authors Caldwell, Daniel J., Mertens, Birgit, Kappler, Kelly, Senac, Thomas, Journel, Romain, Wilson, Peter, Meyerhoff, Roger D., Parke, Neil J., Mastrocco, Frank, Mattson, Bengt, Murray-Smith, Richard, Dolan, David G., Straub, Jürg Oliver, Wiedemann, Michael, Hartmann, Andreas, Finan, Douglas S.
Format Journal Article
LanguageEnglish
Published United States Pergamon 01.04.2016
Blackwell Publishing Ltd
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools are not a substitute for compliance with local regulatory requirements but rather are intended to help manufacturers achieve the general standard of “no discharge of APIs in toxic amounts.” The approaches detailed in the present study identify practices for assessing potential environmental risks from APIs in manufacturing effluent and outline measures that can be used to reduce the risk, including selective application of available treatment technologies. These measures either are commonly employed within the industry or have been implemented to a more limited extent based on local circumstances. Much of the material is based on company experience and case studies discussed at an industry workshop held on this topic. Environ Toxicol Chem 2016;35:813–822. © 2015 The Authors. Environmental Toxicology and Chemistry Published by Wiley Periodicals, Inc. on behalf of SETAC.
AbstractList The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools are not a substitute for compliance with local regulatory requirements but rather are intended to help manufacturers achieve the general standard of "no discharge of APIs in toxic amounts." The approaches detailed in the present study identify practices for assessing potential environmental risks from APIs in manufacturing effluent and outline measures that can be used to reduce the risk, including selective application of available treatment technologies. These measures either are commonly employed within the industry or have been implemented to a more limited extent based on local circumstances. Much of the material is based on company experience and case studies discussed at an industry workshop held on this topic.
The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools are not a substitute for compliance with local regulatory requirements but rather are intended to help manufacturers achieve the general standard of “no discharge of APIs in toxic amounts.” The approaches detailed in the present study identify practices for assessing potential environmental risks from APIs in manufacturing effluent and outline measures that can be used to reduce the risk, including selective application of available treatment technologies. These measures either are commonly employed within the industry or have been implemented to a more limited extent based on local circumstances. Much of the material is based on company experience and case studies discussed at an industry workshop held on this topic. Environ Toxicol Chem 2016;35:813–822. © 2015 The Authors. Environmental Toxicology and Chemistry Published by Wiley Periodicals, Inc. on behalf of SETAC.
The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools are not a substitute for compliance with local regulatory requirements but rather are intended to help manufacturers achieve the general standard of "no discharge of APIs in toxic amounts." The approaches detailed in the present study identify practices for assessing potential environmental risks from APIs in manufacturing effluent and outline measures that can be used to reduce the risk, including selective application of available treatment technologies. These measures either are commonly employed within the industry or have been implemented to a more limited extent based on local circumstances. Much of the material is based on company experience and case studies discussed at an industry workshop held on this topic.The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools are not a substitute for compliance with local regulatory requirements but rather are intended to help manufacturers achieve the general standard of "no discharge of APIs in toxic amounts." The approaches detailed in the present study identify practices for assessing potential environmental risks from APIs in manufacturing effluent and outline measures that can be used to reduce the risk, including selective application of available treatment technologies. These measures either are commonly employed within the industry or have been implemented to a more limited extent based on local circumstances. Much of the material is based on company experience and case studies discussed at an industry workshop held on this topic.
The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools are not a substitute for compliance with local regulatory requirements but rather are intended to help manufacturers achieve the general standard of "no discharge of APIs in toxic amounts." The approaches detailed in the present study identify practices for assessing potential environmental risks from APIs in manufacturing effluent and outline measures that can be used to reduce the risk, including selective application of available treatment technologies. These measures either are commonly employed within the industry or have been implemented to a more limited extent based on local circumstances. Much of the material is based on company experience and case studies discussed at an industry workshop held on this topic. Environ Toxicol Chem 2016; 35:813-822. copyright 2015 The Authors. Environmental Toxicology and Chemistry Published by Wiley Periodicals, Inc. on behalf of SETAC.
Author Murray-Smith, Richard
Straub, Jürg Oliver
Mattson, Bengt
Wiedemann, Michael
Mastrocco, Frank
Kappler, Kelly
Dolan, David G.
Wilson, Peter
Meyerhoff, Roger D.
Hartmann, Andreas
Journel, Romain
Finan, Douglas S.
Senac, Thomas
Parke, Neil J.
Caldwell, Daniel J.
Mertens, Birgit
Author_xml – sequence: 1
  givenname: Daniel J.
  surname: Caldwell
  fullname: Caldwell, Daniel J.
  email: dcaldwel@its.jnj.com
  organization: Johnson & Johnson, NJ, New Brunswick, USA
– sequence: 2
  givenname: Birgit
  surname: Mertens
  fullname: Mertens, Birgit
  organization: Janssen Pharmaceutical Companies of Johnson & Johnson, Belgium, Beerse
– sequence: 3
  givenname: Kelly
  surname: Kappler
  fullname: Kappler, Kelly
  organization: Johnson & Johnson Consumer Group of Companies, New Jersey, Skillman, USA
– sequence: 4
  givenname: Thomas
  surname: Senac
  fullname: Senac, Thomas
  organization: Sanofi, France, Paris
– sequence: 5
  givenname: Romain
  surname: Journel
  fullname: Journel, Romain
  organization: Sanofi, France, Paris
– sequence: 6
  givenname: Peter
  surname: Wilson
  fullname: Wilson, Peter
  organization: Sanofi Bridgewater, New Jersey, USA
– sequence: 7
  givenname: Roger D.
  surname: Meyerhoff
  fullname: Meyerhoff, Roger D.
  organization: Eli Lilly, Indiana, Indianapolis, USA
– sequence: 8
  givenname: Neil J.
  surname: Parke
  fullname: Parke, Neil J.
  organization: Eli Lilly, Indiana, Indianapolis, USA
– sequence: 9
  givenname: Frank
  surname: Mastrocco
  fullname: Mastrocco, Frank
  organization: Pfizer, New York, New York, USA
– sequence: 10
  givenname: Bengt
  surname: Mattson
  fullname: Mattson, Bengt
  organization: LIF, Swedish Association of the Pharmaceutical Industry, Sweden, Stockholm
– sequence: 11
  givenname: Richard
  surname: Murray-Smith
  fullname: Murray-Smith, Richard
  organization: AstraZeneca, United Kingdom, Alderley Park
– sequence: 12
  givenname: David G.
  surname: Dolan
  fullname: Dolan, David G.
  organization: Amgen, California, Thousand Oaks, USA
– sequence: 13
  givenname: Jürg Oliver
  surname: Straub
  fullname: Straub, Jürg Oliver
  organization: F. Hoffmann-La Roche, Basel, Switzerland
– sequence: 14
  givenname: Michael
  surname: Wiedemann
  fullname: Wiedemann, Michael
  organization: Bayer HealthCare, Leverkusen, Germany
– sequence: 15
  givenname: Andreas
  surname: Hartmann
  fullname: Hartmann, Andreas
  organization: Novartis, Basel, Switzerland
– sequence: 16
  givenname: Douglas S.
  surname: Finan
  fullname: Finan, Douglas S.
  organization: GSK, Research Triangle Park, North Carolina, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26183919$$D View this record in MEDLINE/PubMed
BookMark eNqN0ttqFTEUBuAgFbtbBZ9AB7zpzWxzmMnhUopWoeqFVkGQsCaH3bSzZ7ZJpto7H8Fn9EnMsGvFouhVAutbOfCvPbQzjIND6D7BS4IxfeyyWTLC2S20IG1La8mJ3EELLBiuBeVyF-2ldIYx4UqpO2iXljpTRC3QxxjS-fev3zpIzlaw2cQRzGmVx2oNA6zCsKrA5HDhqs0pxDUYN-VgoK9KJTob3JBT2c968kVOcW5x3vdTKd1Ftz30yd27WvfRybOnbw-f18evj14cPjmuDScNq62hqjPK2w4LaznuFONcdlK4RvEGAOPWG8YYN5ZY2hGrvFe2BWO9lMITto8OtueW53-aXMp6HZJxfQ-DG6ekicSSCUx5-z-UkVayRv2bCtFyRjCVhT66Qc_GKQ7lz7NqJOaKNUU9uFJTt3ZWb2JYQ7zUP-P4daOJY0rR-WtCsJ6T1iVpPSdd6PIGNSFDDuOQI4T-Tw31tuFz6N3lXw_WxfzuQ8ruy7WHeK65YKLV718dafZS4XeEtfpD8Q-33sOoYVXmSp-8oWXkytg1gtOW_QD0zdGR
CitedBy_id crossref_primary_10_1590_0103_11042019s312
crossref_primary_10_1016_j_yrtph_2018_09_014
crossref_primary_10_1155_2024_5538398
crossref_primary_10_2174_2667337108666211206151551
crossref_primary_10_1061__ASCE_HZ_2153_5515_0000694
crossref_primary_10_1002_etc_3394
crossref_primary_10_1021_acs_chemrev_1c00631
crossref_primary_10_3390_w16233428
crossref_primary_10_1016_j_watres_2017_09_019
crossref_primary_10_1016_j_envres_2023_117747
crossref_primary_10_1002_ieam_4560
crossref_primary_10_1016_j_scitotenv_2021_151128
crossref_primary_10_1002_ieam_4141
crossref_primary_10_1007_s10311_021_01194_y
crossref_primary_10_1515_limre_2017_0010
crossref_primary_10_1007_s13201_022_01594_7
crossref_primary_10_1016_j_scitotenv_2018_05_325
crossref_primary_10_1007_s13762_023_04880_2
crossref_primary_10_1016_j_jwpe_2019_101039
crossref_primary_10_7759_cureus_68215
crossref_primary_10_1248_yakushi_17_00177_4
crossref_primary_10_1007_s11356_016_6947_z
crossref_primary_10_1016_j_scitotenv_2018_07_240
crossref_primary_10_1039_C7EW00077D
crossref_primary_10_1007_s13762_017_1393_0
crossref_primary_10_1007_s11270_024_07606_3
crossref_primary_10_1016_j_scitotenv_2019_134815
crossref_primary_10_1016_j_talanta_2019_120382
crossref_primary_10_1016_j_trac_2018_02_013
Cites_doi 10.1016/j.ecoenv.2010.05.012
10.1016/j.scitotenv.2012.07.086
10.2166/wst.2011.054
10.1002/ieam.1551
10.1016/j.yrtph.2005.05.005
10.1002/ieam.1268
10.1016/j.chemosphere.2014.02.004
10.1016/j.aquatox.2005.09.009
10.1007/BF03326250
10.1021/es203987b
10.1002/ieam.1311
10.1289/ehp.1104477
10.1016/j.envint.2009.09.002
10.1016/j.jhazmat.2007.07.008
10.1021/es100356f
10.1016/j.envpol.2013.09.013
10.1016/j.envint.2011.06.002
10.1098/rstb.2013.0571
ContentType Journal Article
Copyright 2015 The Authors. Published by Wiley Periodicals, Inc. on behalf of SETAC.
2015 The Authors. Environmental Toxicology and Chemistry Published by Wiley Periodicals, Inc. on behalf of SETAC.
2016 SETAC
Copyright_xml – notice: 2015 The Authors. Published by Wiley Periodicals, Inc. on behalf of SETAC.
– notice: 2015 The Authors. Environmental Toxicology and Chemistry Published by Wiley Periodicals, Inc. on behalf of SETAC.
– notice: 2016 SETAC
DBID FBQ
BSCLL
24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7SN
7SS
7ST
7T7
7TK
7U7
8FD
C1K
FR3
K9.
P64
RC3
SOI
7X8
7S9
L.6
DOI 10.1002/etc.3163
DatabaseName AGRIS
Istex
Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Biotechnology Research Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
Environment Abstracts
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Technology Research Database
Toxicology Abstracts
ProQuest Health & Medical Complete (Alumni)
Ecology Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
Entomology Abstracts
Genetics Abstracts
Biotechnology Research Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Environment Abstracts
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList MEDLINE


MEDLINE - Academic
AGRICOLA
Technology Research Database
Entomology Abstracts
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: FBQ
  name: AGRIS
  url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Ecology
EISSN 1552-8618
EndPage 822
ExternalDocumentID 3992787611
26183919
10_1002_etc_3163
ETC3163
ark_67375_WNG_3M90V135_Z
US201600147625
Genre reviewArticle
Journal Article
Review
GrantInformation_xml – fundername: Whitehouse Station, NJ, USA
GroupedDBID ---
--K
-~X
..I
.3N
.GA
.Y3
05W
0R~
10A
1B1
1OB
1OC
29G
31~
33P
36B
3SF
3V.
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5VS
66C
702
7PT
7X2
7X7
7XC
8-0
8-1
8-3
8-4
8-5
88E
88I
8C1
8FE
8FG
8FH
8FI
8FJ
8G5
8R4
8R5
8UM
8WZ
930
A03
A6W
AAESR
AAEVG
AAFWJ
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCUV
ABEFU
ABHUG
ABJCF
ABJNI
ABPTK
ABPVW
ABUWG
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOD
ACIWK
ACPOU
ACPRK
ACXBN
ACXME
ACXQS
ADAWD
ADBBV
ADDAD
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFKRA
AFPWT
AFRAH
AFVGU
AFZJQ
AGJLS
AHMBA
AI.
AIAGR
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATCPS
ATUGU
AUFTA
AVWKF
AZBYB
AZFZN
AZQEC
AZVAB
BAFTC
BDRZF
BENPR
BFHJK
BGLVJ
BHBCM
BHPHI
BMNLL
BMXJE
BNHUX
BPHCQ
BROTX
BRXPI
BVXVI
BY8
CAG
CCPQU
COF
CS3
D-E
D-F
D0L
D1I
DCZOG
DPXWK
DR2
DRFUL
DRSTM
DU5
DWQXO
EBS
ECGQY
EJD
F00
F01
F04
F5P
FBQ
FEDTE
FYUFA
G-S
G.N
GNUQQ
GODZA
GUQSH
GWYGA
H.T
H.X
HCIFZ
HF~
HMCUK
HVGLF
HZ~
IHE
IX1
J0M
KB.
L6V
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M0K
M1P
M2O
M2P
M41
M7S
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NNB
NQ-
O66
O9-
OHT
P2P
P2W
P2X
P4D
PALCI
PATMY
PDBOC
PQQKQ
PROAC
PSQYO
PTHSS
PYCSY
Q.N
Q11
Q2X
QB0
R.K
RIWAO
RJQFR
RNS
ROL
RPZ
RWI
RX1
SAMSI
SUPJJ
TWZ
UB1
UKHRP
VH1
W8V
W99
WBKPD
WH7
WIH
WIK
WOHZO
WRC
WUPDE
WXSBR
WYISQ
XG1
XIH
XV2
YCJ
ZZTAW
~02
~IA
~KM
~WT
AAHBH
ABEJV
AHBTC
AITYG
ALIPV
BSCLL
HGLYW
24P
5WD
AANHP
AAYCA
ABDFA
ABXVV
ACRPL
ACYXJ
ADIPN
ADNMO
AEUYN
AFWVQ
ALVPJ
OBOKY
OWPYF
ROX
AAYXX
ABGNP
AGORE
AGQPQ
BCRHZ
CITATION
KOP
AAMMB
ACVCV
AEFGJ
AGHNM
AGXDD
AIDQK
AIDYY
AJBYB
AJDVS
CGR
CUY
CVF
ECM
EIF
H13
NPM
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
7QO
7SN
7SS
7ST
7T7
7TK
7U7
8FD
C1K
FR3
K9.
P64
RC3
SOI
7X8
7S9
L.6
ID FETCH-LOGICAL-c6143-dc29bc9fdb07dd60b93668b87e4964aa005fc3336cd1d2b1d9ff9d5acdf887f13
IEDL.DBID DR2
ISSN 0730-7268
1552-8618
IngestDate Fri Jul 11 13:40:32 EDT 2025
Fri Jul 11 18:26:17 EDT 2025
Fri Jul 11 01:34:34 EDT 2025
Wed Aug 13 11:10:28 EDT 2025
Mon Jul 21 06:06:35 EDT 2025
Thu Apr 24 22:53:13 EDT 2025
Tue Jul 01 01:49:49 EDT 2025
Wed Jan 22 16:35:31 EST 2025
Wed Oct 30 09:51:21 EDT 2024
Wed Dec 27 19:26:43 EST 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Wastewater effluent
Active pharmaceutical ingredient
Maturity path
Language English
License Attribution-NonCommercial-NoDerivs
https://creativecommons.org/licenses/by-nc-nd/4.0
2015 The Authors. Environmental Toxicology and Chemistry Published by Wiley Periodicals, Inc. on behalf of SETAC.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c6143-dc29bc9fdb07dd60b93668b87e4964aa005fc3336cd1d2b1d9ff9d5acdf887f13
Notes http://dx.doi.org/10.1002/etc.3163
ark:/67375/WNG-3M90V135-Z
istex:3C175B89615A1E8A50D2315B3777C08065BF658B
Whitehouse Station, NJ, USA
ArticleID:ETC3163
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fetc.3163
PMID 26183919
PQID 1774806934
PQPubID 32741
PageCount 10
ParticipantIDs proquest_miscellaneous_1808370265
proquest_miscellaneous_1803158349
proquest_miscellaneous_1775631028
proquest_journals_1774806934
pubmed_primary_26183919
crossref_primary_10_1002_etc_3163
crossref_citationtrail_10_1002_etc_3163
wiley_primary_10_1002_etc_3163_ETC3163
istex_primary_ark_67375_WNG_3M90V135_Z
fao_agris_US201600147625
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate April 2016
PublicationDateYYYYMMDD 2016-04-01
PublicationDate_xml – month: 04
  year: 2016
  text: April 2016
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Oxford
PublicationTitle Environmental toxicology and chemistry
PublicationTitleAlternate Environ Toxicol Chem
PublicationYear 2016
Publisher Pergamon
Blackwell Publishing Ltd
Publisher_xml – name: Pergamon
– name: Blackwell Publishing Ltd
References Cardoso O, Porcher JM, Sanchez W. 2014. Factory-discharged pharmaceuticals could be a relevant source of aquatic environment contamination: Review of evidence and need for knowledge. Chemosphere 115:20-30.
Deegan AM, Shaik B, Nolan K, Urell K, Oelgemöller M, Tobin J, Morrissey A. 2011. Treatment options for wastewater effluents from pharmaceutical companies. Int J Environ Sci Tech 8:649-666.
Phillips PJ, Smith SG, Kolpin DW, Zaugg SD, Buxton HT, Furlong ET, Esposito K, Stinson B. 2010. Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents. Environ Sci Technol 44:4910-4916.
Kostich MS, Batt AL, Lazorchak JM. 2014. Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation. Environ Pollut 184C:354-359.
Martz M. 2012. Effective wastewater treatment in the pharmaceutical industry. Pharm Eng 32:1-12.
US Environmental Protection Agency. 1995. Final Water Quality Guidance for the Great Lakes System. Final Rule. 40 CFR Part 9. Fed Reg 60:15365-15425.
Monteiro SC, Boxall ABA. 2010. Occurrence and fate of human pharmaceuticals in the environment. Rev Environ Contam Toxicol 202:53-154.
Tischler L, Buzby M, Finan DS, Cunningham VL. 2013. Landfill disposal of unused medicines reduces surface water releases. Integr Environ Assess Manag 9:142-154.
US Environmental Protection Agency. 2008. Drinking Water Contaminant Candidate List 3-Draft. Fed Reg 73:9628-9654.
Gros M, Petrovic M, Ginebreda A, Barcelo D. 2010. Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. Environ Int 36:15-26.
Lundstrom E, Adolfsson-Erici M, Alsberg T, Bjorlenius B, Eklund B, Laven M, Breitholtz M. 2010. Characterization of additional sewage treatment technologies: Ecotoxicological effects and levels of selected pharmaceuticals, hormones and endocrine disruptors. Ecotoxicol Environ Saf 73:1612-1619.
Oppenheimer J, Stephenson R. 2006. Time out: Longer solids retention times can remove some PPCPs. Water Environment and Technology 18:77-82.
Larsson DG, de Pedro C, Paxeus N. 2007. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J Hazard Mater 148:751-755.
Sanchez W, Sremski W, Piccini B, Palluel O, Maillot-Marechal E, Betoulle S, Jaffal A, Ait-Aissa S, Brion F, Thybaud E, Hinfray N, Porcher JM. 2011. Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges. Environ Int 37:1342-1348.
US Environmental Protection Agency. 2009. Drinking Water Contaminant Candidate List 3-Final. Fed Reg 74:51850-51862.
Sarp S, Chon K, Kim IS, Cho J. 2011. Advanced treatment of membrane bioreactor (MBR) effluents for effective wastewater reclamation. Water Sci Technol 63:303-310.
Rudd MA, Ankley GT, Boxall AB, Brooks BW. 2014. International scientists' priorities for research on pharmaceutical and personal care products in the environment. Integr Environ Assess Manag 10:576-587.
Larsson DG. 2014. Pollution from drug manufacturing: Review and perspectives. Philos Trans R Soc Lond B Biol Sci 369:20130571.
Fent K, Weston AA, Caminada D. 2006. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 76:122-159.
Gardner M, Comber S, Scrimshaw MD, Cartmell E, Lester J, Ellor B. 2012. The significance of hazardous chemicals in wastewater treatment works effluents. Sci Total Environ 437:363-372.
Cook SM, VanDuinen BJ, Love NG, Skerlos SJ. 2012. Life cycle comparison of environmental emissions from three disposal options for unused pharmaceuticals. Environ Sci Technol 46:5535-5541.
US Environmental Protection Agency. 2012. Revisions to the Unregulated Contaminant Monitoring Regulation (UCMR 3) for public water systems. Final Rule. 40 CFR Parts 141 and 142. Fed Reg 77:26072-26101.
Murray-Smith RJ, Coombe VT, Gronlund MH, Waern F, Baird JA. 2012. Managing emissions of active pharmaceutical ingredients from manufacturing facilities: An environmental quality standard approach. Integr Environ Assess Manag 8:320-330.
Schwab BW, Hayes EP, Fiori JM, Mastrocco FJ, Roden NM, Cragin D, Meyerhoff RD, D'Aco VJ, Anderson PD. 2005. Human pharmaceuticals in US surface waters: A human health risk assessment. Regul Toxicol Pharmacol 42:296-312.
Boxall AB, Rudd MA, Brooks BW, Caldwell DJ, Choi K, Hickmann S, Innes E, Ostapyk K, Staveley JP, Verslycke T, Ankley GT, Beazley KF, Belanger SE, Berninger JP, Carriquiriborde P, Coors A, Deleo PC, Dyer SD, Ericson JF, Gagne F, Giesy JP, Gouin T, Hallstrom L, Karlsson MV, Larsson DG, Lazorchak JM, Mastrocco F, McLaughlin A, McMaster ME, Meyerhoff RD, Moore R, Parrott JL, Snape JR, Murray-Smith R, Servos MR, Sibley PK, Straub JO, Szabo ND, Topp E, Tetreault GR, Trudeau VL, Van Der Kraak G. 2012. Pharmaceuticals and personal care products in the environment: What are the big questions? Environ Health Perspect 120:1221-1229.
US Environmental Protection Agency. 2015. Drinking Water Contaminant Candidate List 4-Draft. Fed Reg 80:6076-6084.
European Commission. 2010. Directive 2010/75/EU of the European Parliament and of the Council of 24 November 2010 on industrial emissions (integrated pollution prevention and control). Official J Eur Union L334:17-119.
2007; 148
2012; 120
2010; 36
2012
2011
2006; 76
2010
2010; 202
2014; 184C
1998
2009
2008
2005; 42
2007
2006; 18
2006
1995
2011; 37
2015; 80
1992
2008; 73
2012; 77
2011; 8
2012; 32
2014; 115
2013; 9
2010; 44
2014; 369
2009; 74
1995; 60
2010; L334
2011; 63
2016
2015
2014
2013
2012; 46
2012; 437
2010; 73
2012; 8
2014; 10
World Health Organization. (2025010315265570700_etc3163-bib-0021) 2011
European Commission. (2025010315265570700_etc3163-bib-0023) 2010; L334
European Commission. (2025010315265570700_etc3163-bib-0026) 2011
OSPAR Commision. (2025010315265570700_etc3163-bib-0040) 2007
Cardoso (2025010315265570700_etc3163-bib-0005) 2014; 115
European Commission. (2025010315265570700_etc3163-bib-0012) 2008
US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0018) 2012; 77
Pharmaceutical Supply Chain Initiative. (2025010315265570700_etc3163-bib-0055) 2015
US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0041) 2010
Ecologic Institute. (2025010315265570700_etc3163-bib-0013) 2013
Deegan (2025010315265570700_etc3163-bib-0043) 2011; 8
Organisation for Economic Co-operation and Development. (2025010315265570700_etc3163-bib-0048) 1992
Monteiro (2025010315265570700_etc3163-bib-0001) 2010; 202
Organisation for Economic Co-operation and Development. (2025010315265570700_etc3163-bib-0032) 2014
US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0031) 1995
Larsson (2025010315265570700_etc3163-bib-0008) 2014; 369
Cook (2025010315265570700_etc3163-bib-0004) 2012; 46
Martz (2025010315265570700_etc3163-bib-0044) 2012; 32
Derksen (2025010315265570700_etc3163-bib-0045) 2013
US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0024) 2014
US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0025) 1995; 60
US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0042) 2010
European Medicines Evaluation Agency. (2025010315265570700_etc3163-bib-0028) 2006
Phillips (2025010315265570700_etc3163-bib-0007) 2010; 44
US Food and Drug Administration. (2025010315265570700_etc3163-bib-0034) 2006
Lundstrom (2025010315265570700_etc3163-bib-0051) 2010; 73
Schwab (2025010315265570700_etc3163-bib-0030) 2005; 42
US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0019) 2015; 80
US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0033) 2014
Rudd (2025010315265570700_etc3163-bib-0057) 2014; 10
Malinowski (2025010315265570700_etc3163-bib-0052) 2009
US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0017) 2009; 74
Larsson (2025010315265570700_etc3163-bib-0009) 2007; 148
European Commision. (2025010315265570700_etc3163-bib-0038) 2006
European Commission. (2025010315265570700_etc3163-bib-0047) 2006
Water Environment Research Foundation. (2025010315265570700_etc3163-bib-0011) 2015
Kostich (2025010315265570700_etc3163-bib-0050) 2014; 184C
Boxall (2025010315265570700_etc3163-bib-0056) 2012; 120
Fent (2025010315265570700_etc3163-bib-0010) 2006; 76
European Commission. (2025010315265570700_etc3163-bib-0014) 2012
Sanchez (2025010315265570700_etc3163-bib-0006) 2011; 37
Innovative Medicines Initiative. (2025010315265570700_etc3163-bib-0015) 2015
US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0046) 1998
US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0037) 2014
US Food and Drug Administration. (2025010315265570700_etc3163-bib-0035) 2014
Oppenheimer (2025010315265570700_etc3163-bib-0053) 2006; 18
Gardner (2025010315265570700_etc3163-bib-0022) 2012; 437
Sarp (2025010315265570700_etc3163-bib-0054) 2011; 63
European Commision. (2025010315265570700_etc3163-bib-0039) 2014
European Medicines Agency. (2025010315265570700_etc3163-bib-0036) 2015
Caldwell (2025010315265570700_etc3163-bib-0003) 2016
Gros (2025010315265570700_etc3163-bib-0049) 2010; 36
European Chemicals Agency. (2025010315265570700_etc3163-bib-0027) 2011
US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0016) 2008; 73
Tischler (2025010315265570700_etc3163-bib-0002) 2013; 9
European Commission. (2025010315265570700_etc3163-bib-0020) 2012
Murray-Smith (2025010315265570700_etc3163-bib-0029) 2012; 8
References_xml – reference: Deegan AM, Shaik B, Nolan K, Urell K, Oelgemöller M, Tobin J, Morrissey A. 2011. Treatment options for wastewater effluents from pharmaceutical companies. Int J Environ Sci Tech 8:649-666.
– reference: Fent K, Weston AA, Caminada D. 2006. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 76:122-159.
– reference: US Environmental Protection Agency. 2008. Drinking Water Contaminant Candidate List 3-Draft. Fed Reg 73:9628-9654.
– reference: Sanchez W, Sremski W, Piccini B, Palluel O, Maillot-Marechal E, Betoulle S, Jaffal A, Ait-Aissa S, Brion F, Thybaud E, Hinfray N, Porcher JM. 2011. Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges. Environ Int 37:1342-1348.
– reference: Gros M, Petrovic M, Ginebreda A, Barcelo D. 2010. Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. Environ Int 36:15-26.
– reference: Lundstrom E, Adolfsson-Erici M, Alsberg T, Bjorlenius B, Eklund B, Laven M, Breitholtz M. 2010. Characterization of additional sewage treatment technologies: Ecotoxicological effects and levels of selected pharmaceuticals, hormones and endocrine disruptors. Ecotoxicol Environ Saf 73:1612-1619.
– reference: Murray-Smith RJ, Coombe VT, Gronlund MH, Waern F, Baird JA. 2012. Managing emissions of active pharmaceutical ingredients from manufacturing facilities: An environmental quality standard approach. Integr Environ Assess Manag 8:320-330.
– reference: Rudd MA, Ankley GT, Boxall AB, Brooks BW. 2014. International scientists' priorities for research on pharmaceutical and personal care products in the environment. Integr Environ Assess Manag 10:576-587.
– reference: US Environmental Protection Agency. 2012. Revisions to the Unregulated Contaminant Monitoring Regulation (UCMR 3) for public water systems. Final Rule. 40 CFR Parts 141 and 142. Fed Reg 77:26072-26101.
– reference: Oppenheimer J, Stephenson R. 2006. Time out: Longer solids retention times can remove some PPCPs. Water Environment and Technology 18:77-82.
– reference: Larsson DG, de Pedro C, Paxeus N. 2007. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J Hazard Mater 148:751-755.
– reference: Larsson DG. 2014. Pollution from drug manufacturing: Review and perspectives. Philos Trans R Soc Lond B Biol Sci 369:20130571.
– reference: US Environmental Protection Agency. 2015. Drinking Water Contaminant Candidate List 4-Draft. Fed Reg 80:6076-6084.
– reference: Monteiro SC, Boxall ABA. 2010. Occurrence and fate of human pharmaceuticals in the environment. Rev Environ Contam Toxicol 202:53-154.
– reference: Phillips PJ, Smith SG, Kolpin DW, Zaugg SD, Buxton HT, Furlong ET, Esposito K, Stinson B. 2010. Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents. Environ Sci Technol 44:4910-4916.
– reference: European Commission. 2010. Directive 2010/75/EU of the European Parliament and of the Council of 24 November 2010 on industrial emissions (integrated pollution prevention and control). Official J Eur Union L334:17-119.
– reference: Tischler L, Buzby M, Finan DS, Cunningham VL. 2013. Landfill disposal of unused medicines reduces surface water releases. Integr Environ Assess Manag 9:142-154.
– reference: Cardoso O, Porcher JM, Sanchez W. 2014. Factory-discharged pharmaceuticals could be a relevant source of aquatic environment contamination: Review of evidence and need for knowledge. Chemosphere 115:20-30.
– reference: Schwab BW, Hayes EP, Fiori JM, Mastrocco FJ, Roden NM, Cragin D, Meyerhoff RD, D'Aco VJ, Anderson PD. 2005. Human pharmaceuticals in US surface waters: A human health risk assessment. Regul Toxicol Pharmacol 42:296-312.
– reference: Sarp S, Chon K, Kim IS, Cho J. 2011. Advanced treatment of membrane bioreactor (MBR) effluents for effective wastewater reclamation. Water Sci Technol 63:303-310.
– reference: Martz M. 2012. Effective wastewater treatment in the pharmaceutical industry. Pharm Eng 32:1-12.
– reference: Cook SM, VanDuinen BJ, Love NG, Skerlos SJ. 2012. Life cycle comparison of environmental emissions from three disposal options for unused pharmaceuticals. Environ Sci Technol 46:5535-5541.
– reference: Gardner M, Comber S, Scrimshaw MD, Cartmell E, Lester J, Ellor B. 2012. The significance of hazardous chemicals in wastewater treatment works effluents. Sci Total Environ 437:363-372.
– reference: US Environmental Protection Agency. 1995. Final Water Quality Guidance for the Great Lakes System. Final Rule. 40 CFR Part 9. Fed Reg 60:15365-15425.
– reference: US Environmental Protection Agency. 2009. Drinking Water Contaminant Candidate List 3-Final. Fed Reg 74:51850-51862.
– reference: Boxall AB, Rudd MA, Brooks BW, Caldwell DJ, Choi K, Hickmann S, Innes E, Ostapyk K, Staveley JP, Verslycke T, Ankley GT, Beazley KF, Belanger SE, Berninger JP, Carriquiriborde P, Coors A, Deleo PC, Dyer SD, Ericson JF, Gagne F, Giesy JP, Gouin T, Hallstrom L, Karlsson MV, Larsson DG, Lazorchak JM, Mastrocco F, McLaughlin A, McMaster ME, Meyerhoff RD, Moore R, Parrott JL, Snape JR, Murray-Smith R, Servos MR, Sibley PK, Straub JO, Szabo ND, Topp E, Tetreault GR, Trudeau VL, Van Der Kraak G. 2012. Pharmaceuticals and personal care products in the environment: What are the big questions? Environ Health Perspect 120:1221-1229.
– reference: Kostich MS, Batt AL, Lazorchak JM. 2014. Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation. Environ Pollut 184C:354-359.
– year: 2011
– volume: 8
  start-page: 649
  year: 2011
  end-page: 666
  article-title: Treatment options for wastewater effluents from pharmaceutical companies
  publication-title: Int J Environ Sci Tech
– volume: 77
  start-page: 26072
  year: 2012
  end-page: 26101
  article-title: Revisions to the Unregulated Contaminant Monitoring Regulation (UCMR 3) for public water systems. Final Rule. 40 CFR Parts 141 and 142
  publication-title: Fed Reg
– volume: 9
  start-page: 142
  year: 2013
  end-page: 154
  article-title: Landfill disposal of unused medicines reduces surface water releases
  publication-title: Integr Environ Assess Manag
– volume: 202
  start-page: 53
  year: 2010
  end-page: 154
  article-title: Occurrence and fate of human pharmaceuticals in the environment
  publication-title: Rev Environ Contam Toxicol
– volume: 44
  start-page: 4910
  year: 2010
  end-page: 4916
  article-title: Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents
  publication-title: Environ Sci Technol
– volume: L334
  start-page: 17
  year: 2010
  end-page: 119
  article-title: Directive 2010/75/EU of the European Parliament and of the Council of 24 November 2010 on industrial emissions (integrated pollution prevention and control)
  publication-title: Official J Eur Union
– year: 2007
– volume: 76
  start-page: 122
  year: 2006
  end-page: 159
  article-title: Ecotoxicology of human pharmaceuticals
  publication-title: Aquat Toxicol
– volume: 8
  start-page: 320
  year: 2012
  end-page: 330
  article-title: Managing emissions of active pharmaceutical ingredients from manufacturing facilities: An environmental quality standard approach
  publication-title: Integr Environ Assess Manag
– start-page: 284
  year: 2009
  end-page: 303(220)
– volume: 73
  start-page: 1612
  year: 2010
  end-page: 1619
  article-title: Characterization of additional sewage treatment technologies: Ecotoxicological effects and levels of selected pharmaceuticals, hormones and endocrine disruptors
  publication-title: Ecotoxicol Environ Saf
– volume: 184C
  start-page: 354
  year: 2014
  end-page: 359
  article-title: Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation
  publication-title: Environ Pollut
– year: 2016
– volume: 148
  start-page: 751
  year: 2007
  end-page: 755
  article-title: Effluent from drug manufactures contains extremely high levels of pharmaceuticals
  publication-title: J Hazard Mater
– year: 1992
– volume: 115
  start-page: 20
  year: 2014
  end-page: 30
  article-title: Factory‐discharged pharmaceuticals could be a relevant source of aquatic environment contamination: Review of evidence and need for knowledge
  publication-title: Chemosphere
– year: 2014
– year: 2010
– year: 1998
– year: 2012
– volume: 18
  start-page: 77
  year: 2006
  end-page: 82
  article-title: Time out: Longer solids retention times can remove some PPCPs
  publication-title: Water Environment and Technology
– volume: 36
  start-page: 15
  year: 2010
  end-page: 26
  article-title: Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes
  publication-title: Environ Int
– volume: 73
  start-page: 9628
  year: 2008
  end-page: 9654
  article-title: Drinking Water Contaminant Candidate List 3—Draft
  publication-title: Fed Reg
– volume: 120
  start-page: 1221
  year: 2012
  end-page: 1229
  article-title: Pharmaceuticals and personal care products in the environment: What are the big questions
  publication-title: Environ Health Perspect
– volume: 32
  start-page: 1
  year: 2012
  end-page: 12
  article-title: Effective wastewater treatment in the pharmaceutical industry
  publication-title: Pharm Eng
– volume: 80
  start-page: 6076
  year: 2015
  end-page: 6084
  article-title: Drinking Water Contaminant Candidate List 4—Draft
  publication-title: Fed Reg
– year: 2008
– year: 2006
– volume: 437
  start-page: 363
  year: 2012
  end-page: 372
  article-title: The significance of hazardous chemicals in wastewater treatment works effluents
  publication-title: Sci Total Environ
– volume: 42
  start-page: 296
  year: 2005
  end-page: 312
  article-title: Human pharmaceuticals in US surface waters: A human health risk assessment
  publication-title: Regul Toxicol Pharmacol
– volume: 37
  start-page: 1342
  year: 2011
  end-page: 1348
  article-title: Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges
  publication-title: Environ Int
– volume: 74
  start-page: 51850
  year: 2009
  end-page: 51862
  article-title: Drinking Water Contaminant Candidate List 3—Final
  publication-title: Fed Reg
– year: 1995
– volume: 63
  start-page: 303
  year: 2011
  end-page: 310
  article-title: Advanced treatment of membrane bioreactor (MBR) effluents for effective wastewater reclamation
  publication-title: Water Sci Technol
– volume: 369
  start-page: 20130571
  year: 2014
  article-title: Pollution from drug manufacturing: Review and perspectives
  publication-title: Philos Trans R Soc Lond B Biol Sci
– volume: 60
  start-page: 15365
  year: 1995
  end-page: 15425
  article-title: Final Water Quality Guidance for the Great Lakes System. Final Rule. 40 CFR Part 9
  publication-title: Fed Reg
– volume: 10
  start-page: 576
  year: 2014
  end-page: 587
  article-title: International scientists' priorities for research on pharmaceutical and personal care products in the environment
  publication-title: Integr Environ Assess Manag
– volume: 46
  start-page: 5535
  year: 2012
  end-page: 5541
  article-title: Life cycle comparison of environmental emissions from three disposal options for unused pharmaceuticals
  publication-title: Environ Sci Technol
– year: 2015
– year: 2013
– year: 2010
  ident: 2025010315265570700_etc3163-bib-0042
– year: 1992
  ident: 2025010315265570700_etc3163-bib-0048
– year: 2006
  ident: 2025010315265570700_etc3163-bib-0034
– year: 2015
  ident: 2025010315265570700_etc3163-bib-0036
– year: 2007
  ident: 2025010315265570700_etc3163-bib-0040
– year: 2014
  ident: 2025010315265570700_etc3163-bib-0024
– year: 2014
  ident: 2025010315265570700_etc3163-bib-0032
– year: 2013
  ident: 2025010315265570700_etc3163-bib-0013
– volume: 73
  start-page: 1612
  year: 2010
  ident: 2025010315265570700_etc3163-bib-0051
  article-title: Characterization of additional sewage treatment technologies: Ecotoxicological effects and levels of selected pharmaceuticals, hormones and endocrine disruptors
  publication-title: Ecotoxicol Environ Saf
  doi: 10.1016/j.ecoenv.2010.05.012
– start-page: 284
  year: 2009
  ident: 2025010315265570700_etc3163-bib-0052
– year: 2011
  ident: 2025010315265570700_etc3163-bib-0021
– year: 2012
  ident: 2025010315265570700_etc3163-bib-0014
– year: 2014
  ident: 2025010315265570700_etc3163-bib-0033
– year: 2014
  ident: 2025010315265570700_etc3163-bib-0039
– volume: 202
  start-page: 53
  year: 2010
  ident: 2025010315265570700_etc3163-bib-0001
  article-title: Occurrence and fate of human pharmaceuticals in the environment
  publication-title: Rev Environ Contam Toxicol
– volume: 437
  start-page: 363
  year: 2012
  ident: 2025010315265570700_etc3163-bib-0022
  article-title: The significance of hazardous chemicals in wastewater treatment works effluents
  publication-title: Sci Total Environ
  doi: 10.1016/j.scitotenv.2012.07.086
– volume: 77
  start-page: 26072
  year: 2012
  ident: 2025010315265570700_etc3163-bib-0018
  article-title: Revisions to the Unregulated Contaminant Monitoring Regulation (UCMR 3) for public water systems. Final Rule. 40 CFR Parts 141 and 142
  publication-title: Fed Reg
– volume: 63
  start-page: 303
  year: 2011
  ident: 2025010315265570700_etc3163-bib-0054
  article-title: Advanced treatment of membrane bioreactor (MBR) effluents for effective wastewater reclamation
  publication-title: Water Sci Technol
  doi: 10.2166/wst.2011.054
– volume: 10
  start-page: 576
  year: 2014
  ident: 2025010315265570700_etc3163-bib-0057
  article-title: International scientists' priorities for research on pharmaceutical and personal care products in the environment
  publication-title: Integr Environ Assess Manag
  doi: 10.1002/ieam.1551
– volume: 42
  start-page: 296
  year: 2005
  ident: 2025010315265570700_etc3163-bib-0030
  article-title: Human pharmaceuticals in US surface waters: A human health risk assessment
  publication-title: Regul Toxicol Pharmacol
  doi: 10.1016/j.yrtph.2005.05.005
– year: 2014
  ident: 2025010315265570700_etc3163-bib-0037
– volume: 8
  start-page: 320
  year: 2012
  ident: 2025010315265570700_etc3163-bib-0029
  article-title: Managing emissions of active pharmaceutical ingredients from manufacturing facilities: An environmental quality standard approach
  publication-title: Integr Environ Assess Manag
  doi: 10.1002/ieam.1268
– year: 2006
  ident: 2025010315265570700_etc3163-bib-0038
– year: 2013
  ident: 2025010315265570700_etc3163-bib-0045
– volume: 18
  start-page: 77
  year: 2006
  ident: 2025010315265570700_etc3163-bib-0053
  article-title: Time out: Longer solids retention times can remove some PPCPs
  publication-title: Water Environment and Technology
– year: 2014
  ident: 2025010315265570700_etc3163-bib-0035
– year: 2006
  ident: 2025010315265570700_etc3163-bib-0047
– volume: 115
  start-page: 20
  year: 2014
  ident: 2025010315265570700_etc3163-bib-0005
  article-title: Factory-discharged pharmaceuticals could be a relevant source of aquatic environment contamination: Review of evidence and need for knowledge
  publication-title: Chemosphere
  doi: 10.1016/j.chemosphere.2014.02.004
– volume: 76
  start-page: 122
  year: 2006
  ident: 2025010315265570700_etc3163-bib-0010
  article-title: Ecotoxicology of human pharmaceuticals
  publication-title: Aquat Toxicol
  doi: 10.1016/j.aquatox.2005.09.009
– volume: 8
  start-page: 649
  year: 2011
  ident: 2025010315265570700_etc3163-bib-0043
  article-title: Treatment options for wastewater effluents from pharmaceutical companies
  publication-title: Int J Environ Sci Tech
  doi: 10.1007/BF03326250
– year: 1998
  ident: 2025010315265570700_etc3163-bib-0046
– year: 2011
  ident: 2025010315265570700_etc3163-bib-0026
– year: 2010
  ident: 2025010315265570700_etc3163-bib-0041
– volume: 46
  start-page: 5535
  year: 2012
  ident: 2025010315265570700_etc3163-bib-0004
  article-title: Life cycle comparison of environmental emissions from three disposal options for unused pharmaceuticals
  publication-title: Environ Sci Technol
  doi: 10.1021/es203987b
– volume: 9
  start-page: 142
  year: 2013
  ident: 2025010315265570700_etc3163-bib-0002
  article-title: Landfill disposal of unused medicines reduces surface water releases
  publication-title: Integr Environ Assess Manag
  doi: 10.1002/ieam.1311
– year: 2012
  ident: 2025010315265570700_etc3163-bib-0020
– year: 2015
  ident: 2025010315265570700_etc3163-bib-0011
– volume: L334
  start-page: 17
  year: 2010
  ident: 2025010315265570700_etc3163-bib-0023
  article-title: Directive 2010/75/EU of the European Parliament and of the Council of 24 November 2010 on industrial emissions (integrated pollution prevention and control)
  publication-title: Official J Eur Union
– volume: 120
  start-page: 1221
  year: 2012
  ident: 2025010315265570700_etc3163-bib-0056
  article-title: Pharmaceuticals and personal care products in the environment: What are the big questions
  publication-title: Environ Health Perspect
  doi: 10.1289/ehp.1104477
– volume: 36
  start-page: 15
  year: 2010
  ident: 2025010315265570700_etc3163-bib-0049
  article-title: Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes
  publication-title: Environ Int
  doi: 10.1016/j.envint.2009.09.002
– volume: 80
  start-page: 6076
  year: 2015
  ident: 2025010315265570700_etc3163-bib-0019
  article-title: Drinking Water Contaminant Candidate List 4—Draft
  publication-title: Fed Reg
– year: 2016
  ident: 2025010315265570700_etc3163-bib-0003
– volume: 148
  start-page: 751
  year: 2007
  ident: 2025010315265570700_etc3163-bib-0009
  article-title: Effluent from drug manufactures contains extremely high levels of pharmaceuticals
  publication-title: J Hazard Mater
  doi: 10.1016/j.jhazmat.2007.07.008
– volume: 60
  start-page: 15365
  year: 1995
  ident: 2025010315265570700_etc3163-bib-0025
  article-title: Final Water Quality Guidance for the Great Lakes System. Final Rule. 40 CFR Part 9
  publication-title: Fed Reg
– volume: 32
  start-page: 1
  year: 2012
  ident: 2025010315265570700_etc3163-bib-0044
  article-title: Effective wastewater treatment in the pharmaceutical industry
  publication-title: Pharm Eng
– year: 2011
  ident: 2025010315265570700_etc3163-bib-0027
– year: 2006
  ident: 2025010315265570700_etc3163-bib-0028
– volume: 74
  start-page: 51850
  year: 2009
  ident: 2025010315265570700_etc3163-bib-0017
  article-title: Drinking Water Contaminant Candidate List 3—Final
  publication-title: Fed Reg
– volume: 44
  start-page: 4910
  year: 2010
  ident: 2025010315265570700_etc3163-bib-0007
  article-title: Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents
  publication-title: Environ Sci Technol
  doi: 10.1021/es100356f
– volume: 184C
  start-page: 354
  year: 2014
  ident: 2025010315265570700_etc3163-bib-0050
  article-title: Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation
  publication-title: Environ Pollut
  doi: 10.1016/j.envpol.2013.09.013
– volume: 37
  start-page: 1342
  year: 2011
  ident: 2025010315265570700_etc3163-bib-0006
  article-title: Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges
  publication-title: Environ Int
  doi: 10.1016/j.envint.2011.06.002
– volume: 73
  start-page: 9628
  year: 2008
  ident: 2025010315265570700_etc3163-bib-0016
  article-title: Drinking Water Contaminant Candidate List 3—Draft
  publication-title: Fed Reg
– year: 2015
  ident: 2025010315265570700_etc3163-bib-0015
– year: 1995
  ident: 2025010315265570700_etc3163-bib-0031
– year: 2008
  ident: 2025010315265570700_etc3163-bib-0012
– volume: 369
  start-page: 20130571
  year: 2014
  ident: 2025010315265570700_etc3163-bib-0008
  article-title: Pollution from drug manufacturing: Review and perspectives
  publication-title: Philos Trans R Soc Lond B Biol Sci
  doi: 10.1098/rstb.2013.0571
– year: 2015
  ident: 2025010315265570700_etc3163-bib-0055
SSID ssj0016999
Score 2.32211
SecondaryResourceType review_article
Snippet The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts...
SourceID proquest
pubmed
crossref
wiley
istex
fao
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 813
SubjectTerms Active pharmaceutical ingredient
case studies
compliance
Drug Industry
Drug-Related Side Effects and Adverse Reactions
Effluents
Environmental impact
Environmental Pollutants - analysis
Environmental Pollutants - toxicity
Environmental risk
ingredients
manufacturing
Manufacturing industry
Maturity path
Pharmaceutical Preparations - analysis
Pharmaceuticals
risk
Risk Assessment
Risk reduction
toxicity
Toxicology
Waste Water - analysis
wastewater
Wastewater effluent
Title risk‐based approach to managing active pharmaceutical ingredients in manufacturing effluent
URI https://api.istex.fr/ark:/67375/WNG-3M90V135-Z/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fetc.3163
https://www.ncbi.nlm.nih.gov/pubmed/26183919
https://www.proquest.com/docview/1774806934
https://www.proquest.com/docview/1775631028
https://www.proquest.com/docview/1803158349
https://www.proquest.com/docview/1808370265
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9VAEF5sQfDF1mtPrWUFqU9pk91ks_tYpLUILaIeLfqw7FWhek45Jwdsn_oT_I3-Emc2F63UIj4lkFmYzGVnNpn5hpCnJtbcS4S-VLnJSsNVJo3FXhnvXCXqYFJv1eGROBiXL4-r466qEnthWnyI4YMbekbar9HBjZ3v_AINhbeCA6dAoE8s1cJ86PWAHFUIlUZHogFnNROyx53N2U6_8FIkWopmCvkpivbbVcnm5dw1BZ_9FfKxZ7utOTnZXjR2253_gej4f--1Sm53OSndbY3oDrkRJnfJzb2EZ312j-hdigXoPy6-Y8jztIchp82Ufu3GHFGT9k16-vn3T-QUnswC1pQ1c7hH6gV2UqTWSBpimo_S3Cfj_b23zw-ybi5D5iCY88w7pqxT0VvQqBe5VVwIaWUdSiVKY8Cxo-OcC-cLz2zhVYzKV8b5CFtaLPgDsjyZTsIaobWSApiKKnJX1qaWQGMU8yaYADuHHJFnvY6060DLcXbGF93CLTMN4tIorhF5MlCetkAdV9CsgZq1-QRS0-M3DNH14IgI8aAaka2k-2GtmZ1gzVtd6fdHLzQ_VPm7glf6w4hs9MahO3ef6wKSaJkLxUtgY3gMjop_X8wkTBeJphIc87lraCQO3ZC8VNfSIGARE8Dzw9Y4B6bhOAwJbwGrt5KJ_VUSGtSK1_V_JXxEbqG42pqlDbLczBbhMaRjjd0kS6x8tZnc7yfOAjFz
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB61RQguvKELBYKEyiltEieOLU4ValmguwfoQoWQLMcPKrXsVtusBJz4CfxGfgkzzgOKSoU47UoZS5N5eMbOzDcAj7UvmRUEfSkTHeeayVjoinplrDEFL50OvVWjMR9O8pf7xf4SPO16YRp8iP7CjTwj7Nfk4HQhvfkLNRRfC0-cnC3DBRroHc5Tr3vsqJTLMDySTDguMy465Nkk2-xWnopFy17PMEMl4X4-K908nb2G8LNzFT50jDdVJ4cbi7raMF__wHT8zze7BlfatDTaauzoOiy56Q24uB0grb_cBLUVUQ36j2_fKerZqEMij-pZ9KmddBTpsHVGxwe_35JH-GTuqKysPsH_RL2gZorQHRk5H0ak1LdgsrO992wYt6MZYoPxnMXWZLIy0tsKlWp5UknGuahE6XLJc63Rt71hjHFjU5tVqZXeS1toYz3uaj5lt2FlOpu6VYhKKTgy5aVnJi91KZBGy8xqpx1uHmIATzolKdPiltP4jCPVIC5nCsWlSFwDeNRTHjdYHWfQrKKelf6IUlOTNxkB7OEpEUNCMYD1oPx-rZ4fUtlbWah34-eKjWTyNmWFej-Atc46VOvxJyrFPFokXLIc2egfo6_SBxg9dbNFoCk4o5TuHBpBczcEy-W5NIRZlHHk-U5jnT3TeCLGnDfF1evBxv4qCYVqpd-7_0r4EC4N90a7avfF-NU9uEyia0qY1mClni_cfczO6upB8MKfj2c0tw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9VAEN4IRsOL4g2Ogq6JwadC2223u48EOOKFE6MeJfiw2e4FEuCck0NPoj75E_yN_hJmthfFIDE-tUlnk-lcdmbbmW8IeaZ9waxA6EsZ6yjTTEZCl9grY43JeeF06K3aG_DdYfZqP99vqiqxF6bGh-g-uKFnhP0aHXxi_cYv0FB4KzhwcjZHrmc8FmjR2-866KiEyzA7Ei04KlIuWuDZON1oV14IRXNejyFBRdl-uSzbvJi8hujTv00-t3zXRSfH67OqXDff_oB0_L8XWyS3mqSUbtZWdIdcc6O75MZOALT-eo-oTYoV6D-__8CYZ2mLQ06rMT1t5hxRHTZOOjn6_Rs5hSdTh0Vl1RncI_UMWylCbyR1PgxIqe6TYX_nw9Zu1AxmiAxEcxZZk8rSSG9LUKnlcSkZ56IUhcskz7QGz_aGMcaNTWxaJlZ6L22ujfWwp_mEPSDzo_HILRNaSMGBKS89M1mhCwE0WqZWO-1g6xA98rzVkTINajkOzzhRNd5yqkBcCsXVI087ykmN1HEJzTKoWelDkJoavk8RXg_OiBAQ8h5ZC7rv1urpMRa9Fbn6NHih2J6MPyYsVwc9stIah2r8_UwlkEWLmEuWARvdY_BU_P2iR248CzQ5Z5jQXUEjcOqGYJm8kgYRi1IOPC_VxtkxDedhyHgTWL0WTOyvklCgVrw-_FfCJ-Tm2-2-evNy8PoRWUDJ1fVLK2S-ms7cKqRmVfk4-OA56-Azbw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+risk-based+approach+to+managing+active+pharmaceutical+ingredients+in+manufacturing+effluent&rft.jtitle=Environmental+toxicology+and+chemistry&rft.au=Caldwell%2C+Daniel+J&rft.au=Mertens%2C+Birgit&rft.au=Kappler%2C+Kelly&rft.au=Senac%2C+Thomas&rft.date=2016-04-01&rft.issn=1552-8618&rft.eissn=1552-8618&rft.volume=35&rft.issue=4&rft.spage=813&rft_id=info:doi/10.1002%2Fetc.3163&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0730-7268&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0730-7268&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0730-7268&client=summon